Impact of hsCRP on heart disease patients after PCI
The Prognosis of Patients After Coronary Intervention (PCI) : a Multi-center Prospective Study in China
This study is trying to see if measuring a specific protein in the blood can help predict how well heart disease patients do after a procedure to open blocked arteries.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2400 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05614050 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the role of high-sensitivity C-reactive protein (hsCRP) in predicting the prognosis of patients with coronary artery disease (CAD) who have undergone percutaneous coronary interventions (PCI). The study will recruit patients from 14 hospitals across China and will monitor changes in hsCRP levels over one year to assess their correlation with major adverse cardiovascular and cerebrovascular events (MACCE). By understanding the residual inflammation risk (RIR) associated with hsCRP, the study seeks to provide insights into improving patient outcomes post-PCI.
Who should consider this trial
Good fit: Ideal candidates include hospitalized patients aged 18 to 80 with coronary heart disease who are undergoing PCI.
Not a fit: Patients with acute or chronic infections, immune diseases, or those on specific long-term medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management and treatment strategies for patients with CAD, potentially reducing the risk of serious cardiovascular events.
How similar studies have performed: Previous studies in Western populations have shown a correlation between hsCRP levels and cardiovascular risk, but this specific approach in the Chinese population is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who understand and sign the informed consent voluntarily; * Age ≥ 18 years old and ≤ 80 years old, regardless of sex; * The hospitalized patients with coronary heart disease undergoing PCI; * Complete all planned PCI during hospitalization. Exclusion Criteria: * Acute, chronic or recurrent infectious diseases; * Immune diseases or immune-related diseases; * Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapy drugs; * Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive measures; * The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.
Where this trial is running
Wuhan, Hubei
- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Xiang Cheng, Doctor — Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Study coordinator: Miao Yu
- Email: yumiaodavid@126.com
- Phone: +862785726009
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.